Observational studyJournal of neurology2021

Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry.

Michael Guger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.